HAE in the News
The articles listed below are various press releases on Hereditary Angioedema
Page#: 1 2 3 4 5 6 7 8 9 10
Pharming Shares Jump Before Expected Drug Approval
Oct 17, 2007 - www.therapeuticsdaily.com
Shares in Dutch biotechnology firm Pharming rose as much as 17 percent on Wednesday in anticipation of a European decision on its key drug Rhucin, which could make the company profitable, analysts said.
...moreCSL Behring Completes Enrollment of Phase III Clinical Study of C1 Inhibitor in Treating Hereditary Angioedema
Oct 12, 2007 - www.cslbehring.com
CSL Behring announced today that it has completed patient enrollment of a Phase III clinical trial of human pasteurized C1-inhibitor (C1-INH) concentrate to treat patients with hereditary angioedema (HAE), a rare genetic disorder that can lead to painful and sometimes life-threatening attacks of edema (swelling) of the face, airway, abdomen, and extremities ...moreUPDATE 1-Pharming drug gets special FDA status, shares jump
Oct 11, 2007 - www.reuters.com
AMSTERDAM, Oct 11 (Reuters) - Dutch biotechnology firm Pharming (PHAR.AS: Quote, Profile, Research) said the U.S. Food and Drug Administration (FDA) granted a special status to its recombinant human fibrinogen (rhFIB) drug, lifting its shares by 10 percent.
...moreJerini Initiates FDA Submission Process of New Drug Application for Icatibant in the Treatment of HAE
Oct 8, 2007 - www.jerini.com
...moreDyax Gets Composition Of Matter Patent For Lead Product Candidate DX-88 - Quick Facts
Oct 4, 2007 - www.tradingmarkets.com
Dyax Corp. (DYAX | charts | news | PowerRating) announced the issuance of U.S. Patent No. 7,276,480, covering the composition of matter for its lead product candidate DX-88, a recombinant small protein discovered from its proprietary phage display technology, ...moreLev’s Cinryze™ BLA Accepted for Filing by FDA
Oct 1, 2007 - home.businesswire.com
Application for Acute Treatment of Hereditary Angioedema Granted Priority Review. ...morePharming Reports Positive Results In European Placebo-Controlled Trial of Rhucin® in Hereditary Angioedema
Aug 20, 2007 - www.marketwire.com
Independent data monitoring committee advises Pharming to stop placebo arm on ethical grounds
Leiden, The Netherlands, August 20, 2007. Biotech company Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) announced today that it has completed an interim analysis of its European randomized placebo-controlled double-blind clinical study designed to evaluate efficacy and safety of Rhucin® in the treatment of acute attacks of Hereditary Angieoedema ("HAE").
...moreTreatments emerge for a rare and life-threatening disease angioedema
Aug 17, 2007 - www.spiritindia.com
An investigational drug called ecallantide (also known as DX-88 [Dyax Corp., Cambridge, MA]) significantly relieves attacks of a rare, life-threatening disease called hereditary angioedema, report researchers from Children's Hospital Boston and 25 other study sites.
...moreChildren’s Hospital partakes in trial investigating genetic disorder
Aug 12, 2007 - Northwest Arkansas Times
Arkansas Children’s Hospital has begun treatment of the first patient in the a confirmatory national clinical trial for hereditary angioedema, ...moreLev Pharmaceuticals Submits Biologics License Application for Cinryze(TM)
Jul 31, 2007 - biz.yahoo.com
Lev Pharmaceuticals, Inc. ("Lev") (OTC Bulletin Board: LEVP.OB - News) today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of its C1 inhibitor, proposed to be marketed as Cinryze(TM), for the acute treatment of hereditary angioedema (HAE) ...morePage #: 1 2 3 4 5 6 7 8 9 10
0
5
7
3
enrolled and counting...
The US Hereditary Angioedema Assoc.,
Seven Waterfront Plaza,
500 Ala Moana Blvd., Suite 400,
Honolulu, HI 96813, (866) 798-5598
The US HAEA's 2010 corporate sponsors
